GENTIAN DIAGNOST. NO -01
Research GENTIAN DIAGNOST. NO -01 (6FK) on Bullrun: market cap EUR 55.65M, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6FK
- ExchangeF
- CountryNorway
- SectorHealthcare
- IndustryMedical Devices
- CurrencyEUR
- Market capEUR 55.65M
- Dividend yield1.6%
- Financial periodQ2 2026
- RevenueNOK 49.77M
- Net incomeNOK 4.42M
- Free cash flow-NOK 3.30M
- Gross margin55.4%
Valuation Snapshot
latest market cap is EUR 55.65M; dividend yield is 1.6%.
Peer valuation comparison
Latest dividend yield is 1.6% versus a Healthcare sector median of 2.03% (21.2% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-14 | EUR 55.65M | n/a | 1.5% | 0.06 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.06 EUR, yield 1.6%.
About GENTIAN DIAGNOST. NO -01
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GENTIAN DIAGNOST. NO -01's market cap?
GENTIAN DIAGNOST. NO -01's market capitalization is EUR 55.65M.
Does GENTIAN DIAGNOST. NO -01 pay a dividend?
GENTIAN DIAGNOST. NO -01 has a dividend yield of 1.6%.
What does GENTIAN DIAGNOST. NO -01 do?
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe.